LC–MS for the Separation of Biopharmaceuticals Reviewed

-







A recent study published by scientists at the National Institute of Pharmaceutical Education and Research (NIPER) in West Bengal, India highlighted advancements made in analytical technologies for emerging drug modalities and liquid chromatography–mass spectrometry (LC–MS) systems. Their findings were published in the Journal of Chromatography A (1).

The biopharmaceutical industry is growing rapidly in several areas including oncology (2). This stems from numerous innovations that have led to the creation of new drug modalities. Within the past 20 years, new modalities have emerged that involve gene and cell therapies, RNA drugs, and complex biologics, among others. Some of these biopharmaceuticals are close to being approved for clinical use, while others are already on the market. To date, annual sales for new modalitie(outside of mRNA) have reached approximately $20 billion, raising the overall market cap for biopharma companies by over $300 billion, according to research from Boston Consulting Group (2).

However, the analytical development of these products can be challenging. Quantifying the products and components of conjugated molecular structures is vital for guiding therapeutic development for preclinical and clinical research, given how complex they can be. Further, vast amounts of information are needed for measuring these modalities with liquid chromatography–mass spectrometry (LC–MS) techniques. LC–MS can be very sensitive, with high mass accuracy, and a reliable operation, leading to the development of various LC–MS-base; however, these methods have faced different problems, leading to alternative approaches being made.

Developing biomolecules that are complicated and low in concentration requires a skilled LC–MS-based approach and knowledgeable personnel. For accurately quantifying biotherapeutics, target analytes (such as a protein or peptide) are selectively captured from complex samples using hybridliquid chromatography-tandem mass spectrometry (LC–MS/MS) techniques. This is like conventional ligand binding assays (LBA), where hybrid LC–MS/MS only requires one antibody compared to traditional LBAs requiring two antibodies, the scientists wrote.



Comments

Post a Comment

Popular posts from this blog

Cell therapy weekly: partnerships for advancing cell and gene therapies

-
Image
This week: Partnerships to advance cell and gene therapies have been announced, focusing on three key areas: developing gene therapies, enhancing cell and gene therapy manufacturing and developing treatments for difficult-to-treat conditions. The news highlights:Centers of excellence for gene therapy research Advancing cell and gene therapy manufacturing Developing therapies for difficult-to-treat conditions Centers of excellence for gene therapy research The Medical Research Centre (MRC), part of UK Research and Innovation (UKRI; both Swindon, UK) is establishing two Centers of Research Excellence (CoRE) to advance therapies for untreatable diseases, each receiving up to roughly US$64 million over 14 years aiming to transform treatments for diseases such as heart disease, immune disorders and neurodegenerative diseases like Huntington’s disease. Oxford University (UK) will lead the MRC/BHF CoRE in Advanced Cardiac Therapies, which will be co-funded with the British Heart Foundati...
Read more

DBT, CSCR develop 1st human gene therapy for Haemophilia A in India

-
Image
Offering hope to around 136,000 Haemophilia A patients in India, the Department of Biotechnology (DBT), along with the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore, announced that they have successfully executed a first-in-human gene therapy using lentiviral vectors for the disease. Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal and external bleeding episodes. Although rare, India bears the world’s second-largest burden of haemophilia. Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, intravenous (IV) access in children, and low patient acceptance.The single-centre study, which enrolled five participants aged between 22 and 41 years, showed transformational results, according to scientists involved in the research. “The therapy successfully produced zero annualised bleeding rates in all five enrolled participan...
Read more